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 2
Abstract 36 
Introduction: Adequate concentrations of efavirenz in the central nervous system (CNS) are 37 
necessary to supress viral replication but high concentrations may increase the likelihood of CNS 38 
adverse drug reactions. The aim of this investigation was to evaluate efavirenz distribution into the 39 
cerebrospinal fluid (CSF) and brain using a physiologically based pharmacokinetic (PBPK) 40 
simulation for comparison with rodent and human data.  41 
 42 
Methods: Efavirenz CNS distribution was calculated using a permeability-limited model in a virtual 43 
cohort of 100 patients receiving efavirenz (600 mg once-daily). Simulations were then compared 44 
with human data from the literature and rodent data. Wistar rats were administered with efavirenz 45 
(10 mg kg-1) once daily over 5 weeks. Plasma and brain tissue was collected for analysis via LC-46 
MS/MS. 47 
 48 
Results: Median Cmax was predicted to be 3184 ng mL-1 (IQR 2219-4851), 49.9 ng mL-1 (IQR 36.6-49 
69.7) and 50,343 ng mL-1 (IQR 38,351-65,799) in plasma, CSF and brain tissue respectively, tissue 50 
to plasma ratio 15.8. Following 5 weeks of oral dosing of efavirenz (10 mg kg-1), the median plasma 51 
and brain tissue concentration in rats was 69.7 ng mL-1 (IQR 44.9 – 130.6) and 702.9 ng mL-1 (IQR 52 
475.5 – 1018.0) respectively, median tissue to plasma ratio was 9.5 (IQR 7.0 – 10.9). 53 
 54 
Conclusion: Although useful, measurement of CSF concentrations may be an underestimation of the 55 
penetration of antiretrovirals into the brain. Limitations associated with obtaining tissue biopsies and 56 
paired plasma and CSF samples from patients make PBPK an attractive tool for probing drug 57 
distribution.   58 
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Introduction 59 
 60 
Despite its widespread use, patients receiving efavirenz-containing therapy frequently report central 61 
nervous system (CNS) disturbances. Symptoms of efavirenz-associated adverse drug reactions 62 
(ADRs) occur with a high frequency and can include depression, anxiety, abnormal dreams and 63 
hallucinations (1). The majority of patients report development of CNS disorders shortly after 64 
commencing efavirenz therapy with symptoms dissipating during the initial months of therapy. A 65 
minority of patients continue to experience symptoms for the duration of efavirenz use (2). More 66 
recently, efavirenz CNS ADRs have been shown to have more long-term effects (3). 67 
 68 
In addition to the negative impact on the quality of the patient’s life, CNS ADRs may also lead to a 69 
decrease in patient adherence. Poor patient adherence to antiretroviral medication is a major concern, 70 
in particular drugs displaying a low genetic barrier to resistance such as efavirenz (4). The impact of 71 
CNS side effects on patient adherence is not clearly defined. Some previous studies indicate that 72 
patients demonstrate tolerance to CNS side effects with minimal impact on patient adherence (5, 6). 73 
However, a recent study demonstrated 60% of patients reported CNS side effects as the primary 74 
reason for discontinuation vs. 3% of patients receiving alternative antiretroviral therapies (3). 75 
 76 
There is a paucity of information regarding distribution of efavirenz into brain tissue. Due to 77 
impracticalities in obtaining brain tissue from patients, some groups have used concentrations in 78 
cerebrospinal fluid (CSF) as a surrogate for brain concentrations. The majority of pharmacokinetic 79 
(PK) studies have focused on describing efavirenz plasma concentrations and elucidating genetic 80 
factors that contribute to the variability in efavirenz PK or genetic associations to predict patients at 81 
risk of developing CNS toxicity (1, 7, 8). However there are a few small studies that investigated 82 
efavirenz PK in both plasma and CSF. CSF concentrations have been shown to be much lower 83 
(around 0.5%) than plasma. However, even at 0.5% of the plasma concentration efavirenz 84 
concentrations in the CSF exceed the IC50 of efavirenz for wild type HIV (9).  85 
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 86 
The appropriateness of CSF concentrations as a surrogate for brain concentrations is currently the 87 
subject of debate (10-12). It has been demonstrated in guinea pigs that brain tissue concentrations of 88 
nevirapine (NVP) not only differ from those in the CSF but also vary between brain regions (10). 89 
NVP uptake was shown to be 0.32 mL g-1 in the CSF whereas NVP uptake was lower in the choroid 90 
plexus (0.25 mL g-1) and higher in the pituitary (1.61 mL g-1) when compared to the CSF (10). 91 
Indeed, concentrations within CSF have been shown to vary depending on where the sample was 92 
taken for other antiretroviral drugs. Lamivudine has been shown to be 5-fold higher in CSF sampled 93 
from the lumbar region compared to ventricular CSF in rhesus monkeys (11). Although there are no 94 
comparable data for efavirenz in the literature, these data exemplify the challenges associated with 95 
predicting brain tissue concentrations in CSF. 96 
 97 
PBPK modelling is a bottom up approach to simulate drug distribution in virtual patients. The 98 
approach mathematically describes physiological and molecular processes defining PK, integrating 99 
drug-specific properties (such as logP, Caco-2 apparent permeability and affinity for transporters and 100 
metabolic enzymes) and patient-specific factors (such as height, weight, sex, organ volumes and 101 
blood flow) (13). The model presented here is based on a full body PBPK model, supplemented with 102 
a 6-compartment model of the CNS and CSF as previously described (14). 103 
 104 
The aim of this investigation was to evaluate efavirenz distribution into the CSF and brain using 105 
PBPK. Simulated efavirenz PK data were then compared to available experimental data from rodents 106 
and clinical data from humans. 107 
 108 
Materials & Methods 109 
 110 
Animals and treatment 111 
 o
n
 N
ovem
ber 7, 2016 by University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
 5
Male Wistar rats (Charles River UK) weighing 180 – 220 g on arrival were used for PK analysis of 112 
efavirenz. Food and water were provided ad libitum. Following completion of the dosing all animals 113 
were sacrificed using an appropriate schedule 1 method (via exposure to CO2 in a rising 114 
concentration). All animal work was conducted in accordance with the Animals (Scientific 115 
Procedures) Act 1986 (ASPA), implemented by the United Kingdom Home Office.  116 
  117 
Drug Treatment 118 
Eight male Wistar rats were dosed with efavirenz (10 mg kg-1, 2 mL kg-1 0.5% methylcellulose in 119 
dH2O) based on individual weight taken prior to dosing. The selected dose was based on scaling 120 
down the dose administered to adult humans (600mg once daily given to an adult weighing 60/70kg). 121 
The dose was also selected as it has been administered to rats previously in a study examining the 122 
anxiogenic effects where it was shown to induce anxiety in Wistar rats (15). Dosing was 123 
administered once daily via oral gavage over 5 weeks. The animals were terminated (via exposure to 124 
CO2 in a rising concentration) 2 hours after the final dose and blood was collected via cardiac 125 
puncture. Blood samples were centrifuged at 2000g for 10 minutes at 4°C to separate plasma. Plasma 126 
was immediately frozen at -80°C and stored for later analysis. Brain tissue was also collected and 127 
following washing in phosphate buffered saline for 30 seconds 3 times, immediately stored at -30°C 128 
for analysis. 129 
 130 
Rapid Equilibrium Dialysis 131 
The protein binding of efavirenz in brain tissue was performed using rapid equilibrium dialysis 132 
(RED) as described by Liu et al. (16). Untreated rat brain tissue was homogenised in 2 volumes 133 
(W:V) of 1% saline solution. Since efavirenz is highly protein bound, a dilution of brain tissue (10% 134 
and 20% brain tissue were prepared with 1% phosphate buffered saline [PBS]) was used. 200 μl of 135 
brain homogenate was spiked with 5000 ng mL-1 efavirenz and added to the donor chamber. The 136 
receiver chamber contained 350 μl of Sorensons buffer. The RED plate (Thermo, UK) was then 137 
placed in a shaking incubator for 4 hours at 37°C at 100 rpm. 250 μl were removed from the receiver 138 
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 6
chamber and frozen at -80°C for analysis. The fraction of drug unbound (fu) in brain tissue was then 139 
calculated from the diluted brain tissue using the following formula (17): 140 
 141 
ܷ݈݊݀݅ݑݐ݁݀ ݂ݑ =
ቀ1ܦቁ
൤ 1݂ݑሺܽ݌݌ܽݎ݁݊ݐሻ − 1൨ + ቀ
1
ܦቁ
 
 142 
Where fu = fraction unbound and D = dilution factor. 143 
 144 
Sample preparation for bioanalysis 145 
Efavirenz was extracted by protein precipitation. 20µl of internal standard (lopinavir 1000ng mL-1) 146 
was added to 100µl of sample, standard or QC which was then treated with 400µl of ACN. Samples 147 
were then centrifuged at 4000g for 10 minutes at 4°C. The supernatant fraction was transferred to a 148 
fresh glass vial and evaporated, samples were placed in a rotary vacuum centrifuge at 30°C and then 149 
reconstituted in 140 µl of H2O:ACN (60:40). 100µl of the sample was then transferred into 200µl 150 
chromatography vials. 5µl of each sample was injected for analysis by LC-MS/MS.  151 
 152 
Rat brain tissue was homogenised in 3 volumes (W:V) of plasma for 1 minute at maximum power 153 
using a Minilys® homogeniser (Bertin technologies, FR). Extraction was performed using protein 154 
precipitation detailed in the previous section. Recovery was tested at 3 levels (400 ng mL-1 100 ng 155 
mL-1and 20 ng mL-1). Mean recovery was 95% (standard deviation 8.9) and 91% (standard deviation 156 
7.8) for plasma and brain, respectively. Samples generated from the RED experiment were pretreated 157 
with 20% ACN (PBS and Sorensons buffer were spiked with 20% ACN in order to aid efavirenz 158 
solubility in these matrices) and mean recovery was 84% (SD% 11.6). 159 
 160 
Quantification of Efavirenz 161 
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Quantification was achieved via LC-MS/MS (TSQ Endura, Thermo Scientific) operating in negative 162 
mode. The following ions were monitored for quantification in selected reaction monitoring scan: 163 
efavirenz (m/z 315 > 242.1, 244.0 and 250.0) and internal standard, lopinavir (m/z 627 > 121.2, 164 
178.1 and 198.1). A stock solution of 1 mg mL-1 efavirenz was prepared in methanol and stored at 165 
4°C until use. A standard curve was prepared in plasma by serial dilution from 500 ng mL-1 to 1.9 ng 166 
mL-1 and an additional blank solution was also used.  167 
 168 
Chromatographic separation was achieved using a multi step gradient with a Hypersil gold C-18 169 
column (Thermo scientific) using mobile phases A (100% H2O, 5mM NH4HCO2) and B (100% 170 
ACN, 5mM NH4HCO2). Chromatography was conducted over 8.55 minutes at a flow rate of 300 µl 171 
min-1. At the start of each run, mobile phase A was 90% until 0.1 minutes when mobile phase B was 172 
increased to 86% at 0.5 minutes. Mobile phase B was then gradually increased to 92% over 4.5 173 
minutes. Mobile phase B was then increased to 97% at 5.1 minutes which was held until 6 minutes. 174 
Mobile phase A was then increased to 90% and held till the termination of the run at 8 minutes. 175 
Inter- and intra- assay variance in accuracy and precision were <15%. 176 
 177 
PBPK parameters 178 
The full body PBPK model used here has been previously published using equations from the physB 179 
model (Figure 1) (13, 18).  The model generates virtual patients based on a statistical description of 180 
human anatomy. The model simulates flow rates, organ volumes and other tissue volumes based on 181 
anthropometric measures and allometric scaling.  182 
 183 
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 184 
Figure 1 shows a diagram of the full body PBPK model. Figure adapted with authors permission 185 
(18). 186 
 187 
Briefly, the equations required to simulate factors such as volume of distribution were previously 188 
published. Physicochemical properties of efavirenz data (including log P, molecular weight, pKa) 189 
and in vitro data (permeation across Caco-2 cells and protein binding) were gathered from the 190 
literature and incorporated into the full body model (19). Volume of distribution was simulated using 191 
the Poulin and Theil equation (20). This method describes the tissue to plasma ratio based on the 192 
individual organ volumes generated from the physB equations. Elimination clearance was calculated 193 
(using equation 1) using allometric scaling of metabolism of efavirenz in microsomes and accounting 194 
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 9
for activity and abundance of cytochrome P450 (CYP) 2B6, CYP2A6, CYP1A2, CYP3A4 and 195 
CYP3A5, and UGT2B7. 196 
 197 
1. ܶܥܮ௜௡௧ = ܣܾݑ݊݀ܽ݊ܿ݁ ×  ܮ݅ݒ݁ݎ ݓ݁݅݃ℎݐ ×  ܯܲܲܩܮ 198 
 199 
Where abundance is the amount of enzyme expressed per microgram of microsomal protein and 200 
MPPGL is the amount of microsomal protein per gram of liver. Apparent clearance was calculated 201 
expressed as the product of the TCLint of all the enzymes contributing to the metabolism of efavirenz. 202 
Systemic clearance was calculated using equation 2, where Qhv is the hepatic flow rate and fu is the 203 
fraction unbound in plasma (18).  204 
 205 
2. ܥܮ = ொ೓ೡ × ௙௨ × ஼௅ೌ೛೛ொ೓ೡା ஼௅ೌ೛೛ × ೑ೠ  206 
 207 
The CNS portion of the model was based on validated parameters describing CNS and CSF 208 
physiology and anatomy (14). A schematic of this model is shown in Figure 2. Physiological and 209 
physicochemical properties used are displayed in Table 1. The equations used in the model presented 210 
here are as follows: 211 
 212 
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 213 
Figure 2 shows a diagram of the CNS component of the PBPK model to describe efavirenz 214 
movement within the CNS. The brain compartment is comprised of the total volume of extra cellular 215 
fluid (ECF) and intracellular space (ICS). 216 
 217 
 218 
The equations used in the model presented here are as follow: 219 
 220 
3. ݈݋݃ܲܵ =  −2.19 + 0.262 ݈݋݃ܦ + 0.0583 ݒܽݏ௕௔௦௘ − 0.00897 ܶܲܵܣ 221 
 222 
Equation 3 shows a 3-descriptor QSAR model of permeability surface area product (log PS) of the 223 
blood brain barrier (BBB) developed by Liu et al. (21). The three descriptors are logD (octanol/water 224 
partition coefficient at pH 7.4), vasbase (van der Waals surface area of the basic atoms) and TPSA 225 
(van der Waals polar surface area). Permeability surface area product of the blood CSF barrier was 226 
calculated by dividing the permeability surface area product of the BBB by 1000, to reflect the 227 
smaller surface area of the blood CSF barrier (22). 228 
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 229 
4. ∆ாி௏ಳೝ∆௧ = ݌ݏܾ ∗ ቀ
ாி௏ಲೝ∗௙௨
ோ − ܧܨ ஻ܸ௥ ∗ ݂ݑ஻௥ቁ − ܳ௘௖௙ ∗ ܧܨ ஻ܸ௥ ∗ ݂ݑ஻௥ 230 
 231 
Equation 4 describes the movement of efavirenz from arterial plasma to the brain where 232 
concentration of arterial efavirenz (EFVAr), fraction unbound in plasma (fu), blood to plasma ratio 233 
(R), concentration of efavirenz in the brain (EFVBr), flow of brain extracellular fluid (Qecf), and 234 
fraction unbound in brain (fuBr). 235 
 236 
5. ∆ாி௏಴ೄಷ ಽೇ∆௧ = ݌ݏ݁ ∗ ቀ
ாி௏ೇ೐∗௙௨
ோ ቁ − ݌ݏ݁ ∗ ܧܨ ௅ܸ௏ ∗ ݂ݑ஼ௌி + ܳ௘௖௙ ∗ ܧܨ ஻ܸ௥ ∗ ݂ݑ஻௥ − ܳ௖௦௙ ∗237 
ܧܨ ௅ܸ௏ 238 
 239 
6. ∆ாி௏಴ೄಷ ೅ಷೇ∆௧ = ݌ݏ݁ ∗ ቀ
ாி௏ೇ೐∗௙௨
ோ ቁ − ݌ݏ݁ ∗ ܧܨ்ܸ ி௏ ∗ ݂ݑ஼ௌி + ܳ௖௦௙ ∗ ܧܨ ௅ܸ௏ − ܳ௖௦௙ ∗ ܧܨ்ܸ ி௏ 240 
 241 
7. ∆ாி௏಴ೄಷ ಴ಾ∆௧ = ݌ݏ݁ ∗ ቀ
ாி௏ೇ೐∗௙௨
ோ ቁ − ݌ݏ݁ ∗ ܧܨ ஼ܸெ ∗ ݂ݑ஼ௌி + ܳ஼ௌி ∗ ܧܨ்ܸ ி௏ − ܳ௖௦௙ ∗ ܧܨ ஼ܸெ 242 
 243 
8. ∆ாி௏಴ೄಷ ೄಲೄ∆௧ = ܳ௖௦௙ ∗ ܧܨ ஼ܸெ − ܳ௖௦௙ ∗ ܧܨ ௌܸ஺ௌ 244 
 245 
Equations 5 to 8 describe the movement of efavirenz from the brain to CSF, including movement 246 
across the blood CSF barrier. The CSF is subdivided into 4 compartments left ventricle (LV), third 247 
and fourth ventricle (TFV), cisterna magna (CM) and the subarachnoid space (SAS) where 248 
concentration of efavirenz in veins (EFVVe), fraction unbound in plasma (fu), blood to plasma ratio 249 
(R), concentration of efavirenz in the brain (EFVBr), concentration of efavirenz in the CSF 250 
compartments (EFVCSF), flow of brain extracellular fluid (Qecf), flow of CSF (Qcsf), fraction unbound 251 
in CSF (fuCSF) and fraction unbound in brain (fuBr). 252 
 253 
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Simulation Design 254 
A virtual cohort of 100 patients was generated and a once-daily dose of efavirenz (600 mg) was 255 
simulated over 5 weeks. Patient age (minimum 18 maximum 60), weight (minimum 40kg, maximum 256 
100kg), height (minimum 1.5 meters maximum 2.1 meters) and body mass index (minimum 18, 257 
maximum 30) were generated from random normally distributed values. The PK in plasma, CSF and 258 
brain tissue were recorded during the final 24 hours at steady state. Plasma and CSF PK simulations 259 
were compared with previous data generated from clinical trials. Brain tissue to plasma ratios were 260 
also calculated and compared to data generated in rodents. 261 
 262 
Materials 263 
Male Wistar rats were purchased from Charles River (Oxford, UK). Efavirenz powder (>98% pure) 264 
was purchased from LGM Pharma Inc (Boca Raton, USA). All other consumables were purchased 265 
from Sigma Aldrich (Dorset, UK). 266 
 267 
Results 268 
The protein binding of efavirenz in brain tissue was determined using rapid equilibrium dialysis. The 269 
mean (± standard deviation) concentration of efavirenz detected in the receiver chamber was 209.7 ± 270 
33.4 ng mL-1, and 165 ± 22.0 ng mL-1 10% and 20% brain homogenate respectively. The fraction 271 
unbound in brain tissue (fuBr) was calculated to be 0.00181 and 0.00212 in 10% and 20% brain 272 
homogenate, respectively. The average fuBr was 0.00197. 273 
 274 
Following 5 weeks of oral dosing of efavirenz (10 mg kg-1), the median plasma concentration of 275 
efavirenz in rats was 69.7 ng mL-1 (IQR 44.9 – 130.6). Median efavirenz concentrations in brain 276 
tissue were 702.9 ng mL-1 (IQR 475.5 – 1018.0). The median tissue to plasma ratio was 9.5 (IQR 7.0 277 
– 10.9). 278 
 279 
 280 
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Simulation 281 
A standard dosing schedule of efavirenz (600 mg once daily) was simulated in 100 patients for the 282 
duration of 5 weeks. The results for efavirenz concentrations in plasma (Figure 3A), CSF (Figure 283 
3B) and brain tissue (Figure 3C) were all taken from the final 24 hours of the simulation. 284 
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 287 
The maximum concentration (Cmax), minimum concentration (Cmin) and area under the curve 288 
(AUC24) of efavirenz in plasma were 3916 ng mL-1 (IQR 3155-5153), 2537 ng mL-1 (IQR 1942-289 
3779) and 76,991 ng.h mL-1 (IQR 62,170-107,560). The CSF was predicted to have lower 290 
concentrations of efavirenz Cmax 50.96 ng mL-1 (IQR 38.23-69.09), Cmin 47.8 ng mL-1 (IQR 36.1-291 
66.7) and AUC24 1193 ng.h mL-1 (IQR 898-1649). At 24 hours efavirenz in the CSF was 1.6% of 292 
plasma concentrations. The simulation predicted efavirenz concentrations in the brain to exceed CSF 293 
and plasma, Cmax 50,973 ng mL-1 (IQR 39,122-66,177), Cmin 49,566 ng mL-1 (IQR 38,044-64,374) 294 
and AUC24 1,207,542 ng.h mL-1 (IQR 926,900-1,567,974). The brain tissue to plasma partition ratio 295 
at 24 hours was 15.8.  296 
 297 
The absorption constant (Ka) was predicted to be 0.19 h-1 (IQR, 0.18-0.21). Volume of distribution 298 
(VSS) and elimination clearance (Cl) were predicted to be 2.15 l kg-1 (IQR 2.06-2.31) 4.56 l h-1 (IQR 299 
3.52-5.33) respectively. The fraction absorbed (fa) of efavirenz was predicted to be median 0.46 300 
(IQR, 0.44-0.49) and was used to calculate apparent VSS and apparent Cl, 323.31 l-1 (IQR 308.31-301 
346.28) and 9.79 l h-1 (7.54-11.41) respectively. 302 
 303 
Comparison with clinical data 304 
The simulated PK parameters in plasma produced by the model were in agreement with data 305 
published from human trials and population PK studies (popPK). Table 2 shows the results from the 306 
simulation and a number of clinical studies and popPK studies. The mean/median observed plasma 307 
concentrations of EFV ranged from 1973 ng mL-1 to 3180 ng mL-1 (9, 23-26).  Simulated Cl, VSS and 308 
Ka were 1.04 fold, 1.28 fold and 0.6 fold different compared to observed data (26). The average 309 
simulated CSF concentrations were 49.9 ng mL-1 (IQR 36.6-69.7) compared to a range of 11.1 ng 310 
mL-1 to 16.3 ng mL-1 observed in previously published clinical studies (9, 23). 311 
 312 
 313 
 o
n
 N
ovem
ber 7, 2016 by University of Liverpool Library
http://aac.asm
.org/
D
ow
nloaded from
 
 16
Discussion  314 
The presented data show that the PBPK model predicts efavirenz to accumulate in the brain in 315 
concentrations that far exceed those in the CSF. Human CSF concentrations were gathered from 316 
relatively small cohorts (Best N=80, Yilmaz N=1 and Tashima N=10) and may not fully represent 317 
CSF concentrations larger populations. Indeed, concentrations of efavirenz in the brain were 318 
predicted to exceed even plasma concentrations, with a brain to plasma ratio of 15.8. The rodent data 319 
presented here supports the model prediction of a higher concentration of efavirenz in brain tissue, 320 
with a median tissue to plasma ratio of 9.5. Recently, efavirenz has been demonstrated to accumulate 321 
in the brain tissue of a macaque. Following 8 days of orally administered efavirenz (60 mg kg-1) the 322 
concentrations in plasma and CSF were 541 and 3.30 ng mL-1 respectively. Concentrations of 323 
efavirenz in the cerebellum and basal ganglia were 6.86 µg g-1 (tissue to plasma ratio 12.7) and 2.01 324 
µg g-1 (tissue to plasma ratio 3.7) respectively (27).  325 
 326 
Currently only one study has examined efavirenz concentrations in human brain tissue (28). This 327 
study showed similar brain concentrations to historical CSF values and are in disagreement with the 328 
data presented here. While participants in this analysis had efavirenz detectable in intracardiac serum 329 
using a qualitative assay, reliable dosing information was not routinely available since the final care 330 
setting varied between individuals (home, hospice, or hospital). Given this uncertainty regarding the 331 
final dosing interval, no precise information was available on the time of last dose, which 332 
complicates interpretation of the reported brain concentrations. If the last efavirenz dose was 333 
administered, for example, 3 days prior to death, then the brain tissue concentrations may not 334 
accurately reflect those that occur in living, adherent patients. However, efavirenz has been shown to 335 
display long plasma half-life (40 to 52 hours) (29). This would indicate patients would have had 336 
ceased receiving efavirenz for many days or having poor adherence in order to explain the very 337 
low concentrations observed. Despite this the data predicted by the model is supported by robust 338 
data generated from the brain tissue concentrations from rats and monkeys (27). 339 
 340 
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Accumulation of efavirenz in brain tissue may be driven by physicochemical properties of efavirenz, 341 
in particular lipophilicity. Since efavirenz is highly lipophilic (logP 4.6) and has high accumulation 342 
in multiple cell types, it shows high cellular permeation (19). The brain has a high fat content, with 343 
approximately 60% of the brain consisting of fat (30). An additional factor that favours distribution 344 
is the high degree of protein binding of efavirenz. In plasma, efavirenz is highly protein bound (fu 345 
0.01) (31). Protein binding in the CSF is much lower leading to more free efavirenz, fu 0.238 (29).  346 
The data presented here from rapid equilibrium dialysis shows efavirenz fu in rodent brain tissue to 347 
be 0.00197. Taken collectively, the combination of low fu and affinity for the lipophilic environment 348 
of the brain favour accumulation of efavirenz in the CNS. Lipophilicity has been shown to be a 349 
significant factor in uptake of drugs into the brain (32). Lipophilicity, but not plasma protein binding, 350 
was shown to correlate with uptake of benzodiazepines, for example, into the brain. However, this 351 
study did not consider fu in the brain and plasma fu may not be a good indicator of brain fu. Kalvass 352 
et al examined the fu in plasma and brain tissue of 34 drugs covering multiple drug classes. The data 353 
presented showed that plasma fu both under and overestimated brain fu depending on the drug (33). 354 
 355 
Although this is the first study to employ PBPK modelling to investigate efavirenz distribution into 356 
the CNS, PBPK has been used previously to investigate efavirenz dose optimisation, drug-drug 357 
interactions and PK in special populations (19, 34). 358 
 359 
Limitations of this work include that the presented model does not take into account genetic 360 
variability (i.e. CYP2B6 variants), the brain fu values were generated in rodent brain rather than 361 
human brain, the current model is not able to estimate local concentrations in individual brain 362 
regions, and permeability of efavirenz was calculated using a QSAR model of passive permeability 363 
which often rely on extrapolated data from animals with important differences to humans (21, 35). 364 
The CSF concentrations predicted by the model were approximately 3 fold greater than observed in 365 
human patients. This indicates that the interactions with efavirenz and the blood CSF barrier may not 366 
have been accurately represented. The permeability of efavirenz at the blood CSF barrier was 367 
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adjusted for the decreased surface area of the blood CSF barrier, 1000 times less than the BBB (22). 368 
The assumption that the permeability of the two barriers is equal may be incorrect. However, these 369 
aspects could be expanded in future modelling strategies as the necessary input data emerges.  370 
The BBB is highly effective at excluding xenobiotics from the CNS. Tight cellular junctions prevent 371 
paracellular transport of drugs and the metabolising enzymes and transport proteins remove drugs 372 
from the CNS. As such, another potential limitation of the model that warrants further elaboration is 373 
that distribution of efavirenz across the BBB may not be governed purely by passive permeability. 374 
The potential influence of influx and efflux transporters was not considered because efavirenz is not 375 
classified as substrate of any transporters and effects of transporters on efavirenz PK have not been 376 
described. The model presented here potentially may be improved upon in the future if efavirenz is 377 
demonstrated to be a substrate for such transporters.  378 
 379 
Numerous studies have linked efavirenz plasma concentrations to clinical evidence of CNS toxicity. 380 
Other studies have shown that efavirenz readily passes the BBB and is present in CSF. The 381 
simulations presented here indicate plasma and CSF may underestimate efavirenz exposure within 382 
the brain. Limitations associated with obtaining tissue biopsies and paired plasma and CSF samples 383 
from patients make PBPK modelling an attractive tool for estimating such drug distribution. 384 
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Model Parameter Value Reference
 
Molecular Weight 
LogP 
pKa 
Caco-2 permiability 
(10-6 cm/s) 
 
Fraction unbound 
Plasma 
CSF 
Brain tissue 
 
PSB 
PSE 
 
Qcsf (mL/min) 
Qecf (mL/min) 
 
315.7 
4.6 
10.2 
2.5 
 
 
 
0.01 
0.238 
0.00197 
 
2.47 
0.00247 
 
0.175 
0.4 
 
(19) 
(19)  
(19) 
(19) 
 
 
 
(31) 
(29) 
 
 
 
 
 
(14) 
(14) 
Brain ICS (mL) 
Brain ECF (mL) 
CSF LV (mL) 
960 
240 
22.5 
(14) 
(14) 
(14) 
CSF TFV (mL) 22.5 (14) 
CSF CM (mL) 7.5 (14) 
CSF SAS (mL) 90 (14) 
 530 
Table 1 shows the physiological and physicochemical variables used to generate the PBPK model. 531 
Intracellular space (ICS), extra cellular fluid (ECF), left ventricle (LV), third and fourth ventricles 532 
(TFV), cisterna magna (CM) and sub arachnoid space (SAS). 533 
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  Simulated data 
Yilmaz et al 
2012* (22) 
Best et al 2011 
(9) 
Tashima et al 1999 
(23) 
Sánchez et al 
2011 (24) 
Csajka et al 2003 
(25) 
  Mean Median Median Median Mean Mean Mean 
Plasma 
concentration 
(ng ml-1) 
3183  
(SD ±447) 
3184  
(IQR 2219-4851) 
3718  
(range 2439-4952) 
2145  
(IQR 1384-4423) 
1973.8  
(range 792.2-2950.9) 
3180  
(SD ±1610) 
  
Plasma AUC 
(ng.h mL-1) 
91924  
(SD ±51619) 
76991  
(IQR 62170-
107560) 
86,280         
Apparent Cl 
(L h-1) 
9.29  
(SE ±0.26) 
9.79  
(IQR 7.54-11.44) 
      9.61  
(SE ±0.38) 
9.4  
(SE ±0.36) 
Aparent VSS  
(L kg-1) 
329.43  
(SE ±2.38)  
323.31  
(IQR 308.31-
346.28) 
      291  
(SE ±44.81) 
252  
(SE ±35.28) 
Ka 
(h-1) 
0.20  
(SD ±0.02) 
0.19  
(IQR 0.18-0.21) 
        0.3  
(SE ±0.09) 
CSF 
concentration 
(ng mL-1) 
49.9  
(SD ±1.2) 
49.9  
(IQR 36.6-69.7) 
16.3  
(range 7.3-22.3) 
13.9  
(IQR 4.1-21.2) 
11.1  
(SD 2.1-18.6) 
    
CSF AUC  
(ng.h mL-1) 
1401  
(SD ±809) 
1193  
(IQR 898-1649) 
380         
Brain tissue 
concentration 
(ng mL-1) 
50312.5  
(SD ±438) 
50343  
(IQR 38351-65799) 
          
Brain tissue 
AUC  
(ng.h mL-1) 
1397820 
(SD ±815657) 
1207542  
(IQR 926900-
1567974) 
          
 534 
Table 2 shows the results from the simulation and a number of human trials and POP PK studies. Results are presented as either mean (± standard 535 
deviation [SD] or standard error [SE]) or median (± interquartile range [IQR]). Mean and median are presented to allow comparison of simulated and 536 
clinical. * all samples in this study were obtained from a single patient over 24 hours. 537 
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